IPO Profiles from April 2011

21ViaNet (China) Inc.

Beijing, China

86-10-8456-2121

www.21vianet.com

Exchange and Ticker: Nasdaq: VNET

Filing Range: 13M shares @ $12 to $13

Offering Price: $15

Offering Size: $195M

IPO Date: 4/21/11

Close on First Day: $18.80

Close on 4/29/11: $15.51

Ordinary Shares Outstanding: 53.8M

Market Capitalization on 4/29/11: $834.4M

Underwriters: Morgan Stanley/Underwriters: Barclays Capital/Underwriters: JP Morgan

Co-manager: Piper Jaffray Inc/ William Blair & Co/ Pacific Crest Securities Inc

Company Counsel: Skadden Arps Slate Meagher & Flom

Manager Counsel: Davis Polk & Wardwell

Auditor: Ernst & Young LLP

Total Funding Raised: $65M

COMPANY DESCRIPTION

Operates as an Internet Service Provider (ISP). The company operates as an ISP service supplier in China. Its main business includes Internet Data Center (IDC) service, Content Delivery Network (CDN), Enterprise Data Center (EDC) service and Data Center based industry solutions.

COMPETITION

Information Security One Limited, Nsfocus Information Technology Co. Ltd.

VENTURE BACKERS

CBC Capital, Matrix Partners, GGV Capital, Emerging Markets Partnership

STOCK HOLDINGS OF VC FUNDS

(For company directors or owners of 5% or more of the company’s shares.)

No. of Shares Value Percentage of

Owner as of 4/21/11 as of 4/30/11 ownership after offering

GGV Capital 26.8M $415.6M 8.30%

Matrix Partners 20M $310.1M 6.2%

Meritech Capital Partners 17M $263.4M 5.3%

FUNDING ROUNDS

No. of Round

Date Investors Amount Valuation

7/14/00 1 $5M $68.5M

1/23/07 1 $20M n/a

4/1/08 3 $40M n/a

1/14/11 1 n/a n/a

FINANCIALS

12/31/08 12/31/09 12/31/10

Total Revenue: n/a n/a n/a

Net Income: -$2.68M -$0.87M -$38.70M

EPS: n/a n/a n/a

Ellie Mae Inc.

Pleasanton, Calif.

925-227-7000

www.elliemae.com

Exchange and Ticker: NYSE: ELLI

Filing Range: 7.5M shares @9 to $11

Offering Price: $6

Offering Size: $45M

IPO Date: 4/15/11

Close on First Day: $6.77

Close on 4/29/11: $7.05

Shares Outstanding: 20.7M

Market Capitalization on 4/29/11: $145.6M

Underwriters: Barclays Capital

Co-manager: William Blair & Co/ Morgan Keegan Inc/ Piper Jaffray Inc

Company Counsel: Latham & Watkins

Manager Counsel: Wilson Sonsini Goodrich & Rosati

Auditor: Grant Thornton LLP

Total Funding Raised: $48.5M

COMPANY DESCRIPTION

Provides software and services for the mortgage industry. The company connects loan originators to customers, partners, lenders, underwriters and service providers. Electronic Mortgage provides online transaction platform and products which includes: point-of-sale websites, loan origination software, lender loan-import software and document software and services. The company offers online transaction platform for the mortgage companies in the United States to do business online with lenders and settlement service providers.

VENTURE BACKERS

Charter Venture Capital, Alta Partners, Alloy Ventures, RS Investments, Fannie Mae, H&Q Asia Pacific, GKM Ventures, Stanford University, Osprey Ventures

STOCK HOLDINGS OF VC FUNDS

(For company directors or owners of 5% or more of the company’s shares.)

No. of Shares Value Percentage of

Owner as of 4/15/11 as of 4/30/11 ownership after offering

Charter Venture Capital 7.1M $50M 34%

Alta Partners 5.6M $39.4M 27%

Alloy Ventures 3.9M $27.5M 18%

FUNDING ROUNDS

No. of Round

Date Investors Amount Valuation

12/31/97 1 $500K n/a

5/31/99 2 $1.5M n/a

7/31/99 1 $500K n/a

9/29/99 4 $10M n/a

5/4/00 6 $28M $165M

12/31/01 4 $5M n/a

12/21/05 2 $3M n/a

FINANCIALS

12/31/07 12/31/08 12/31/09

Total Revenue: $38.5M $33.6M $37.7M

Net Income: $438K -$1.1M $1.6M

EPS: $.05 -$.11 $.17

Responsys Inc.

San Bruno, Calif.

650-745-1700

www.responsys.com

Exchange and Ticker: Nasdaq: MKTG

Filing Range: 6.6M shares @8.5 to $10

Offering Price: $12

Offering Size: $79.4M

IPO Date: 4/21/11

Close on First Day: $15.40

Close on 4/29/11: $15.98

Shares Outstanding: 44.1M

Market Capitalization on 4/29/11: $706M

Underwriters: Morgan Stanley/Underwriters: Credit Suisse

Co-manager: Pacific Crest Securities Inc/ William Blair & Co/ JMP Securities LLC

Company Counsel: Fenwick & West LLP

Manager Counsel: Davis Polk & Wardwell

Auditor: Deloitte & Touche LLP

Total Funding Raised: $57.3M

COMPANY DESCRIPTION

Provides a platform for permission-based direct marketing on the Internet. The company provides a platform for permission marketing that helps businesses acquire and retain customers on the Internet. Responsys delivers a hosted, integrated suite of analytic and e-mail campaign applications for managing online customer profiles, optimizing customer interactions and measuring performance across online channels including websites, e-mail, and e-commerce. Responsys has integrated closed-loop web analytics with e-mail response and web purchasing behavior data, enabling precise marketing ROI calculations.

COMPETITION

Connectify Inc.

VENTURE BACKERS

Sigma Partners, Redpoint Ventures, Accel Partners, Foundation Capital, RSA Capital, RB Webber & Co. Lighthouse Capital Partners, Windspeed Ventures

STOCK HOLDINGS OF VC FUNDS

(For company directors or owners of 5% or more of the company’s shares.)

No. of Shares Value Percentage of

Owner as of 4/21/11 as of 4/30/11 ownership after offering

Foundation Capital 79M $127M 17.30%

Sigma Partners 7.4M $119.1M 16.30%

Accel Partners 6.7M $108M 14.70%

Redpoint Ventures 4.3M $68.3M 9.30%

RB Webber & Co. 3.3M $52.4M 5.20%

FUNDING ROUNDS

No. of Round

Date Investors Amount Valuation

12/16/98 4 $5M $14.6M

1/13/00 5 $18.1M $201M

3/29/01 5 $24.7M $78.3M

3/31/03 8 $9.4M n/a

FINANCIALS

12/31/08 12/31/09 12/31/10

Total Revenue: $50.1M $66.6M $94.1M

Net Income: $20.5M $5.9M $8.6M

EPS: $0.35 $0.02 $0.08

Sagent Pharmaceuticals Inc.

Schaumburg, Ill.

847-908-1600

www.sagentpharma.com

Exchange and Ticker: Nasdaq: SGNT

Filing Range: 5M shares @ $14 to $16

Offering Price: $16

Offering Size: $92M

IPO Date: 4/20/11

Close on First Day: $19.90

Close on 4/29/11: $20.41

Shares Outstanding: 27M

Market Capitalization on 4/29/11: $550M

Underwriters: Morgan Stanley/Underwriters: Bank of America Merrill Lynch/Underwriters: Jefferies & Co Inc

Co-manager: Needham & Co LLC/ RBC Capital Markets

Company Counsel: Kirkland & Ellis

Manager Counsel: Davis Polk & Wardwell

Auditor: Ernst & Young LLP

Total Funding Raised: $144M

COMPANY DESCRIPTION

Sagent Pharmaceuticals Inc. operates as a pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products. It offers injectable products in the therapeutic areas of cardiovascular, anti-infective/antibacterial, antineoplastic agent, and antiemetic. The company’s products also include heparin sodium injections; and ANEclear, a disposable anesthesia recovery device that enables clinicians to remove unwanted anesthetic gases from their patients’ brain, blood, and lungs at the end of the surgical procedure. The company various packaging options, including premix bags, prefilled syringes, single-dose vials, and pharmacy bulk package vials.

COMPETITION

Direct Therapeutics, Amphastar Pharmaceuticals

VENTURE BACKERS

Vivo Ventures, Capricorn Investment Group, undisclosed venture investor

STOCK HOLDINGS OF VC FUNDS

(For company directors or owners of 5% or more of the company’s shares.)

No. of Shares Value Percentage of

Owner as of 4/20/11 as of 4/30/11 ownership after offering

China Renaissance Capital Investment 3.2M $65.1M 11.90%

Vivo Ventures 8.9M $183M 33.40%

FUNDING ROUNDS

No. of Round

Date Investors Amount Valuation

3/2/07 2 $20M n/a

9/27/07 1 $33M n/a

8/29/08 2 $15.2M n/a

5/20/09 3 $30M n/a

4/8/10 2 $40M n/a

9/14/10 1 $6M n/a

FINANCIALS

12/31/08 12/31/09 12/31/10

Total Revenue: $12M $29.2M $74.1M

Net Income: -$30.5 -$30.5M -$24.5M

EPS: -$2.5 -$2.2 -$1.6

Sequans Communications SA

Paris, France

33-1-7072-1600

www.sequans.com

Exchange and Ticker: NYSE: SQNS

Filing Range: 7.7M shares @ $11 to $13

Offering Price: $10

Offering Size: $77M

IPO Date: 4/15/11

Close on First Day: $8.25

Close on 4/29/11: $10.26

Shares Outstanding: 34.5M

Market Capitalization on 30/04/2011: $354M

Underwriters: UBS Investment Bank/Underwriters: Jefferies & Co Inc

Co-manager: Robert W Baird & Co Inc/ Needham & Co LLC/ Natixis

Company Counsel: Orrick Herrington & Sutcliffe LLP

Manager Counsel: Jones Day

Auditor: Ernst & Young LLP

Total Funding Raised: $38M

COMPANY DESCRIPTION

Develops wireless broadband solutions. The company supplies silicon and embedded software for WiMAX-based systems. Sequans Communications develops software solutions such as System-on-Chip, which makes it possible to build PHY and MAC layers. It focuses on signal processing and MAC protocols, which translates to a SoC that enables the development of broadband wireless systems.

VENTURE BACKERS

SGAM Private Equity, Cap Decisif Management SAS, I-Source Gestion SA

Add Partners, Kennet Venture Partners, Vision Capital, Vision Capital Management, Motorola Solutions Venture Capital, Reliance Venture Asset Management, CDC Entreprises SAS, Alcatel-Lucent Ventures, Swisscom Ventures

STOCK HOLDINGS OF VC FUNDS

(For company directors or owners of 5% or more of the company’s shares.)

No. of Shares Value Percentage of

Owner as of 4/15/11 as of 4/30/11 ownership after offering

Add Partners, Ltd. 4.5M $46.6M 12.7%

I-Source Gestion SA 3.4M $35.3M 9.6%

Kennet Venture Partners 3.3M $34.3M 9.3%

CDC Entreprises SAS 1.6M $16.7M 4.6%

Motorola Solutions Venture Capital 1.5M $15.2M 4.10%

Vision Capital 1.8M $18.8M 5.10%

FUNDING ROUNDS

No. of Round

Date Investors Amount Valuation

6/24/04 2 $1.8M n/a

2/22/05 5 $9.3M n/a

4/13/06 1 $3.2M n/a

7/24/06 6 $24M n/a

11/27/06 1 n/a n/a

2/11/08 4 n/a n/a

11/19/09 2 n/a n/a

FINANCIALS

12/31/08 12/31/09 12/31/10

Total Revenue: $22.7M $19.6M $68.5M

Net Income: -$8.3M -$16.9M -$2.7<

EPS: -$0.4 -$0.7 -$0.1

Tranzyme Pharma Inc.

Sherbrooke, Quebec

819-820-6840

www.tranzyme.com

Exchange and Ticker: Nasdaq: TZYM

Filing Range: 13.5M @ $11 to $13

Offering Price: $4

Offering Size: $54M

IPO Date: 4/11/11

Close on First Day: $4.11

Close on 4/29/11: $4.17

Shares Outstanding: 24M

Market Capitalization on 4/29/11: $98.87 M

Underwriters: Citi

Co-manager: BMO Capital Markets/ Canaccord Genuity/ Stifel Nicolaus & Co Inc

Company Counsel: Goodwin Procter LLP

Manager Counsel: Ropes & Gray

Auditor: Ernst & Young LLP

Total Funding Raised: $36M

COMPANY DESCRIPTION

Tranzyme Inc. discovers, develops, and commercializes small molecule therapeutics. The company plans to discover product candidates based on its proprietary Macrocyclic Template Chemistry (MATCH) technology platform. Its principal product candidates include ulimorelin, an intravenous ghrelin agonist entering Phase III clinical development for the management of postoperative ileus. The company also intends to develop TZP-201, a motilin antagonist for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, a ghrelin antagonist targeting obesity and other metabolic diseases. It offers services for the treatment of acute and chronic gastrointestinal (GI) motility disorders in the United States and internationally.

VENTURE BACKERS

Quaker BioVentures Inc., H.I.G. Capital, Thomas, McNerney & Partners, Business Development Bank of Canada, Pacific Rim Ventures Co., Fonds de Solidarite des Travailleurs du Quebec, Investissement Desjardins, BioCapital Inc., Innovatech Sud Du Quebec, Redmont Venture Partners, Research Triangle Ventures, Greer Capital Advisors, MedTech Partners Inc.

STOCK HOLDINGS OF VC FUNDS

(For company directors or owners of 5% or more of the company’s shares.)

No. of Shares Value Percentage of

Owner as of 4/04/11 as of 4/30/11 ownership after offering

Business Development Bank of Canada 1.2M $5.2M 9.40%

Investissement Desjardins 1.3M $5.3M 5.30%

H.I.G. Capital 2.2M $9.1M 12.70%

Quaker BioVentures Inc. 2.2M $9.1M 10.80%

Thomas, McNerney & Partners 2.2M $9.1M 12.70%

FUNDING ROUNDS

No. of Round

Date Investors Amount Valuation

9/30/97 1 $72K n/a

12/30/97 1 $14K n/a

3/31/98 2 $2.8M n/a

12/18/98 1 $326K n/a

6/30/99 1 $339K n/a

12/2/99 1 $250K n/a

3/7/00 1 $750K n/a

6/1/01 4 $4.4M n/a

5/1/02 4 $2M n/a

6/14/02 1 $1.9M n/a

5/13/05 13 $3.2M n/a

1/5/07 1 $2.8M n/a

11/1/07 7 $2.1M n/a

2/1/08 2 $4.9M n/a

10/2/08 7 $7.2M n/a

2/27/09 1 n/a n/a

6/5/09 4 $1.4M n/a

6/24/10 3 $2M n/a

FINANCIALS

12/31/08 12/31/09 12/31/10

Total Revenue: $0.4M $0.7M $8.5M

Net Income: -$21.8M -$11.2M -$7.3M

EPS: -$155.6 -$79.7 -$52.1

Zipcar Inc.

Cambridge, MA

617-995-4231

www.zipcar.com

Exchange and Ticker: Nasdaq: ZIP

Filing Range: 8.33M shares @ $14 to $16

Offering Price: $18

Offering Size: $174.3M

IPO Date: 4/14/11

Close on First Day: $28

Close on 4/29/11: $25.79

Shares Outstanding: 38.6M

Market Capitalization on 4/29/11: $996M

Underwriters: Goldman Sachs & Co/Underwriters: JP Morgan

Co-manager: Cowen/ Needham & Co LLC/ Oppenheimer & Co Inc

Company Counsel: Latham & Watkins

Manager Counsel: Ropes & Gray

Auditor: PricewaterhouseCoopers

Total Funding Raised: $59.3M

COMPANY DESCRIPTION

Zipcar Inc. provides car sharing and car club services. It operates a car sharing network for members in metropolitan areas and on university campuses. The company provides self-service vehicles that are located in reserved parking spaces throughout the neighborhoods where they live and work. It provides transportation alternative for individuals, businesses, universities and government agencies in Massachusetts, Illinois, New York, California, District of Columbia, Canada and United Kingdom.

COMPETITION

Flexcar, Enterprise Rental Car, Budget Rental Car, Hertz, Dollar Rental Car, Alamo Car Rental, Avis Rent A Car System, LLC, Enterprise Rent-A-Car Co., Hertz Global Holdings Inc.

VENTURE BACKERS

Meritech Capital Partners, Greylock Partners, Benchmark Capital, Boston Community Capital, Globespan Capital Partners, Pinnacle Ventures, Revolution Living

STOCK HOLDINGS OF VC FUNDS

(For company directors or owners of 5% or more of the company’s shares.)

No. of Shares Value Percentage of

Owner as of 4/14/11 as of 4/30/11 ownership after offering

Revolution Living 6.9M $178M 18%

Benchmark Capital 3.8M $98M 9.9%

Greylock Partners 2.1M $54.2M 5.6%

FUNDING ROUNDS

No. of Round

Date Investors Amount Valuation

1/11/01 4 $1.3M n/a

10/31/03 1 $3M n/a

7/11/05 1 $10M n/a

11/16/06 6 $25M n/a

3/31/10 3 n/a n/a

12/15/10 2 $21M n/a

FINANCIALS

12/31/08 12/31/09 12/31/10

Total Revenue: $106M $131.2M $186.1M

Net Income: -$4.7M -$3M -$14.1M

EPS: -$1.1 -$0.7 -$2.7

Source: Thomson Reuters